# EDGAR Filing Document

**Accession Number:** 0001867096
**File Stem:** 0001867096-26-000022
**Filing Date:** 2026-4
**Character Count:** 2533
**Document Hash:** 52a750e53c276dc4e4d62942aafd3676
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001867096-26-000022.hdr.sgml**: 20260423

**ACCESSION NUMBER**: 0001867096-26-000022

**CONFORMED SUBMISSION TYPE**: DEFA14A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260423

**DATE AS OF CHANGE**: 20260423

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Xeris Biopharma Holdings, Inc.
- **CENTRAL INDEX KEY:** 0001867096
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 871082097
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** DEFA14A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-40880
- **FILM NUMBER:** 26889620

**BUSINESS ADDRESS:**
- **STREET 1:** 1375 WEST FULTON STREET, SUITE 1300
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60607
- **BUSINESS PHONE:** 844-445-5704

**MAIL ADDRESS:**
- **STREET 1:** 1375 WEST FULTON STREET, SUITE 1300
- **CITY:** CHICAGO
- **STATE:** IL
- **ZIP:** 60607

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**SCHEDULE 14A INFORMATION**

**Proxy Statement Pursuant to Section 14(a) of the**

**Securities Exchange Act of 1934**

**(Amendment No.)**

---

| | | |
|:---|:---|:---|
| Filed by the Registrant 🗹  | Filed by the Registrant 🗹  | Filed by a Party other than the Registrant ◻ |
| Check the appropriate box: | Check the appropriate box: | Check the appropriate box: |
| ◻ | Preliminary Proxy Statement | Preliminary Proxy Statement |
| ◻ | **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))** | **Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))** |
| ◻ | Definitive Proxy Statement | Definitive Proxy Statement |
| 🗹 | Definitive Additional Materials | Definitive Additional Materials |
| ◻ | Soliciting Material under §240.14a-12 | Soliciting Material under §240.14a-12 |

---

**XERIS BIOPHARMA HOLDINGS, INC.** 

**(Name of Registrant as Specified in its Charter)**

**(Name of Person(s) Filing Proxy Statement, if other than the Registrant)**

---

| | |
|:---|:---|
| Payment of Filing Fee (Check the appropriate box): | Payment of Filing Fee (Check the appropriate box): |
| 🗹 | No fee required. |
| ◻ | Fee previously paid with preliminary materials. |
| ◻ | Fee computed on table in exhibit required by Item 25(b) per Securities Exchange Act of 1934 Rules 14a-6(i)(1) and 0-11. |

---

------

![xersnaa_pagex1.jpg](xersnaa_pagex1.jpg)

------

![xersnaa_pagex2.jpg](xersnaa_pagex2.jpg)

<br>